More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

Merck & Co.'s approval from the US Food and Drug Administration (FDA) of Keytruda (pembrolizumab), a drug to treat melanoma, is a key development not only for Merck, but for the industry as other companies seek to advance immunotherapies in the...
DCAT Value Chain Insights

BIO, PhRMA, GPhA, EGA as well as Pfizer, Sanofi, Novartis, Genentech, AbbVie, Boehringer Ingelheim, and Novo Nordisk offer input on the FDA's draft guidance on the clinical studies and related analytical testing needed to support biosimilarity....
DCAT Value Chain Insights

Amgen announced last week a restructuring plan that would reduce its global workforce by 12% to 15% and close facilities in Washington and Colorado. As Amgen moves forward with this plan, how do its current commercial portfolio and pipeline fare...
DCAT Value Chain Insights

The injectables market has been particularly active this month with three deals announced or closed. A look at the gains in product positions and manufacturing capabilities from recent deals. The injectables market is ramping up with three...